R. Just

Phase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib.

J. Goldman, L. Rosen, B. Schwartz, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.

J. Leonard, C. Redfern, J. Gutheil, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: Preliminary results

L. Rosen, L. Chap, S. Limentani, 2008 .

Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib

L. Rosen, J. Goldman, R. Savage, 2012, Cancer.

Abstract B101: Safety, tolerability, and pharmacokinetics of IPI-493, an oral Hsp90 inhibitor, in patients with advanced cancers.

N. Senzer, P. LoRusso, J. Cortes, 2011 .

A phase I study of sonepcizumab (S), a humanized monoclonal antibody to sphingosine-1-phosphate (S1P), in patients with advanced solid tumors.

L. Rosen, A. Dorr, M. Gordon, 2010 .

A phase I/II trial of the combination of bevacizumab, oxaliplatin, and sorafenib in patients with metastatic melanoma

L. Frakes, E. McClay, A. Bessudo, 2008 .